Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 16,380 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Central Nervous System Disease Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Utilizing Senior Companions to Enhance Dementia Care

NCT03667924
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
PorchLight Project
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 17, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

NCT00939523
View directory record Official record
Conditions
Pituitary Adenomas, Prolactinomas
Interventions
Lapatinib
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 17, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

NCT04836559
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
JNJ-40411813, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 69 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Orlando, Florida • Port Orange, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 17, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study

NCT01246479
View directory record Official record
Conditions
Japanese Encephalitis
Interventions
Blood draw, IC51 has given in the parent study IC51-322
Procedure · Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
9 Months to 20 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 17, 2026, 1:53 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

NCT06704269
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
YTB323
Genetic
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Orange, California • Winston-Salem, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 17, 2026, 1:53 AM EDT
Completed Phase 2 Interventional

Carotid With Bivalirudin Angioplasty

NCT00812383
View directory record Official record
Conditions
Carotid Artery Disease
Interventions
RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 17, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Results available

A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)

NCT03571256
View directory record Official record
Conditions
Tourette Syndrome
Interventions
TEV-50717, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 16 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
19
States / cities
Gainesville, Florida • Gulf Breeze, Florida • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 17, 2026, 1:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Chronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin

NCT02266329
View directory record Official record
Conditions
Posttraumatic Headache, Combat Disorders, Post Concussion Syndrome, Headache, Mild Traumatic Brain Injury, Posttraumatic Migraine
Interventions
prazosin hydrochloride, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 17, 2026, 1:53 AM EDT
Terminated Not applicable Interventional

Activity-Dependent Transspinal Stimulation in SCI

NCT03669302
View directory record Official record
Conditions
Spinal Cord Injuries, Paraplegia, Spinal, Tetraplegia/Tetraparesis, Paraplegia, Spastic
Interventions
Robotic gait training, Robotic gait training and low-frequency transspinal stimulation, Robotic gait training and high-frequency transspinal stimulation
Other · Device
Lead sponsor
City University of New York
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Staten Island, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 17, 2026, 1:53 AM EDT
Recruiting No phase listed Observational

Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)

NCT04543253
View directory record Official record
Conditions
Cushing Syndrome
Interventions
MUSE biofeedback
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 17, 2026, 1:53 AM EDT
Completed Phase 2 Interventional

Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder

NCT03056053
View directory record Official record
Conditions
Insomnia Disorder
Interventions
Zolpidem
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Santa Monica, California • Atlanta, Georgia • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 17, 2026, 1:53 AM EDT
Completed Not applicable Interventional

COPE-Co-morbidities, Parkinson's Disease and Exercise

NCT01361724
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Physical therapy, Group Exercise Class, Home Program
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
40 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Oct 17, 2026, 1:53 AM EDT
Terminated No phase listed Observational

Bone Graft Materials Observational Registry

NCT00974623
View directory record Official record
Conditions
Degenerative Disc Disease, Herniated Disc, Spinal Stenosis, Spondylolithesis, Spinal Deformity, Cervical Myelopathy, Failed Back Surgery Syndrome, Spinal Cord Neoplasms
Interventions
Bone graft substitute, autograft or allograft
Device
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
12
States / cities
San Francisco, California • Atlanta, Georgia • Carrollton, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 17, 2026, 1:53 AM EDT
Completed Phase 1 Interventional

ABT-751 in Treating Young Patients With Refractory Solid Tumors

NCT00036959
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ABT-751
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
3
States / cities
Chicago, Illinois • Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 17, 2026, 1:53 AM EDT
Completed Not applicable Interventional

Upper Extremity Function Before and After Hippotherapy in Children With Autism Spectrum Disorder and/or Cerebral Palsy

NCT06530680
View directory record Official record
Conditions
Autism Spectrum Disorder, Cerebral Palsy
Interventions
Hippotherapy
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
6 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 17, 2026, 1:53 AM EDT
Active, not recruiting No phase listed Observational

Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product

NCT02698579
View directory record Official record
Conditions
Cerebral Adrenoleukodystrophy (CALD), Adrenoleukodystrophy (ALD), X-Linked Adrenoleukodystrophy (X-ALD)
Interventions
No interventional drug product utilized in this follow-up study
Genetic
Lead sponsor
Genetix Biotherapeutics Inc.
Industry
Eligibility
Up to 19 Years · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2038
U.S. locations
4
States / cities
Los Angeles, California • Palo Alto, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 17, 2026, 1:53 AM EDT
Recruiting No phase listed Observational

Oxidative Stress and Inflammatory Biomarkers in Gaucher Disease

NCT02437396
View directory record Official record
Conditions
Gaucher Disease Type I, Oxidative Stress, Inflammation
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 17, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years

NCT01389596
View directory record Official record
Conditions
Epilepsy, Partial Seizures
Interventions
Pregabalin add-on therapy
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
4 Years to 16 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
20
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 17, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

NCT03037203
View directory record Official record
Conditions
Excessive Sleepiness, Parkinson Disease
Interventions
JZP-110, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
35 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
Los Angeles, California • San Diego, California • Boulder, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 17, 2026, 1:53 AM EDT
Recruiting Phase 4 Interventional

A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

NCT07633470
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Zunveyl®
Drug
Lead sponsor
Alpha Cognition, Inc
Industry
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
20
States / cities
Irvine, California • Orange, California • Aventura, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 1:53 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Male Fertility Program

NCT01467869
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2040
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 17, 2026, 1:53 AM EDT
Completed No phase listed Observational Results available

Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®

NCT00937794
View directory record Official record
Conditions
Hunter Syndrome
Interventions
Neurobehavioral testing, Visual and auditory assessments
Behavioral · Other
Lead sponsor
Shire
Industry
Eligibility
32 Months to 18 Years · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 17, 2026, 1:53 AM EDT
Withdrawn Phase 3 Interventional

Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

NCT02174094
View directory record Official record
Conditions
Dravet Syndrome
Interventions
Clobazam, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
1 Year to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
8
States / cities
Los Angeles, California • Orlando, Florida • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 17, 2026, 1:53 AM EDT
Recruiting Not applicable Interventional

Just-In-Time Adaptive Interventions (JITAIs) in a Digital Mental Health Intervention for Middle-Aged and Older Adults With Chronic Pain

NCT06978166
View directory record Official record
Conditions
Chronic Pain, Depression, Anxiety
Interventions
Just-In-Time Adaptive Interventions (JITAIs), Wysa for Chronic Pain
Other · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
45 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 17, 2026, 1:53 AM EDT